Context Therapeutics Inc.

CNTX Nasdaq CIK: 0001842952

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 2001 MARKET STREET, PHILADELPHIA, PA, 19103
Mailing Address 2001 MARKET STREET, PHILADELPHIA, PA, 19103
Phone 267-225-7416
Fiscal Year End 1231
EIN 863738787

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events April 2, 2026 View on SEC
8-K Current report of material events March 23, 2026 View on SEC
10-K Annual financial report March 23, 2026 View on SEC
8-K Current report of material events March 13, 2026 View on SEC
8-K Current report of material events February 27, 2026 View on SEC
4 Insider stock transaction report February 23, 2026 View on SEC
4 Insider stock transaction report February 23, 2026 View on SEC
4 Insider stock transaction report February 23, 2026 View on SEC
4 Insider stock transaction report February 23, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 17, 2026 View on SEC

Annual Reports

10-K March 23, 2026
  • Active drug pipeline with three candidates (CTIM-76, CT-95, CT-202) in early development for cancer treatments.
  • Strategic partnerships with companies like Integral Molecular, BioAtla, and Lonza Sales for research, development, and manufacturing support.
View Analysis

Material Events

8-K Legal Issue March 13, 2026
High Impact
  • Enhanced Board Accountability & Shareholder Empowerment
  • Alignment with Corporate Governance Best Practices
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.